Medicare Plans provide coverage for Aduhelm and other medical expenses. contentious Alzheimer’s treatment From the drugmaker Biogen, the Centers for Medicare & Medicaid Services announced Tuesday.

CMS announced that only Medicare beneficiaries will have access to the drug. It is meant for patients with Alzheimer’s disease in its early stages.

This drug was approved by the U.S. as the first to slow the cognitive decline of people with Alzheimer’s. However, some doctors refused to prescribe it due to mixed data that supported Biogen’s application. Food and Drug Administration. FDA approved this drug in an expedited process last June. However, the FDA asked that the company continue to investigate it so as to verify its effectiveness or to risk withdrawing the treatment.

CMS is still awaiting a final ruling. Following the final CMS decision, a public comment period of 30 days will take place. This is where public members can give feedback to CMS. An official decision is expected to be announced in April.

However, the Tuesday ruling will have significant implications on Medicare and how drug prescriptions are made in the future.

More than 6 Million Americans currently live in the United States. Living with Alzheimer’s disease, which is a progressive brain disorder that can affect memory, reasoning, and behavior. to the Alzheimer’s Association. The vast majority of Americans with the disease are old enough to receive Medicare.

The FDA approved all other medications for Alzheimer’s. They are not intended to slow down the progression of the disease. sixth-leading cause of death in the United States, according to the Centers for Disease Control and Prevention.

The monoclonal antibody from Biogen is administered as an intramuscular infusion once every four weeks. The drug targets beta-amyloid in the brain, which scientists suspect plays an important role in the development of the disease. Experts say it’s not clear if lowering beta-amyloid levels has an effect on the progression of the disease.

Expect to pay approximately $1,500 for the treatment. Medicare billions of dollars a yearPremiums for Medicare beneficiaries have been substantially increased by the government.

CMS is unable to provide treatment due to its high price and the potential demand. announced in November that it would increase monthly premiums 15% for Medicare Part B beneficiaries. From $148.50 to $170.10 per year in 2021, this is the largest price hike in program history. But there is more. MondayXavier Becerra (secretary for the Department of Health and Human Secret) asked the agency to reassess the premium hike it had made after Biogen cut the cost of its drug by half.

Some doctors may be tempted to recommend the treatment because of the lower cost out-of-pocket due to Medicare. However, patients who may not have the ability to afford the entire price may still refuse to accept it.

Even though Medicare covers the drug, some doctors are skeptical because of previous statements or confusing data from the company.

Biogen stopped two clinical trials of the drug in 2019 after an analysis showed it to be unlikely. Following an analysis that showed that the drug worked at higher dosages, Biogen announced that the company would seek approval from the FDA.

Last June saw the agency clear the drug, a deviation from its independent panel made up of outside experts. They concluded that there was not enough evidence to show that the drug had slowed the progress of the disease. disease. At least three members of the panel have resigned in protest following the agency’s approval.

It drug’s side effects include brain swelling and bleeding.

In July, acting FDA Commissioner Dr. Janet Woodcock called for a government investigation into contacts between some of her agency’s drug reviewers and Biogen.